Categories
Change Password!
Reset Password!
Long-term care residents exhibit robust and balanced immune responses to RSV vaccines, suggesting robust protection that could last up to two years.
A new immunobridging study published in ‘Journal of the American Medical Directors Association’ highlighted promising antibody responses to respiratory syncytial virus (RSV) vaccines among long-term care facility (LTCF) residents, strengthening the case for their use in this vulnerable group.
Although recent Phase 3 trials for RSV vaccines included few LTCF residents, this prospective non-randomized intervention trial by Ann R. Falsey et al. aimed to assess their immune response (immunogenicity) compared to community-dwelling (CD) adults, where the vaccines had shown high efficacy.
The trial involved adults aged 60 and older from two LTCFs, with participants receiving RSV vaccine. Blood specimens were collected before and 30 days after vaccination to gauge the antibody levels and viral neutralization activity. Respiratory illnesses that occurred during the study were monitored.
Results from 70 LTCF residents and 76 CD adults revealed that the serum IgG geometric mean fold rise (GMFR) showed no significant difference between the CD adults and LTCF residents. Similarly, viral neutralization titers (12.8 versus 15.5) were comparable between the two groups. Based on geometric mean titers and GMFR, the immune responses to the RSV vaccine in LTCF residents fulfilled the criteria for noninferiority when compared to the CD cohort.
Journal of the American Medical Directors Association
Short-Term Immunogenicity of Licensed Subunit RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Compared to Community-Dwelling Older Adults
Ann R. Falsey et al.
Comments (0)